A GLP‐1/GLP‐2 receptor dual agonist to treat NASH : Targeting the gut‐liver axis and microbiome

Therapeutic pipeline in nonalcoholic steatohepatitis

(2021) Raj Vuppalanchi et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2-dependent pathway in mice

(2020) Jenna Elizabeth Hunt et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

FXR Agonists as Therapy for Liver Disease

(2020) Jay H. Hoofnagle   HEPATOLOGY

Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease

(2019) Shun He et al.   NATURE

Differential Action of TGR5 Agonists on GLP-2 Secretion and Promotion of Intestinal Adaptation in Piglet Short Bowel Model

(2019) Sen Lin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum

(2019) Amanda Cheung et al.   HEPATOLOGY

Epidemiology of chronic liver diseases in the USA in the past three decades

(2019) Zobair M Younossi et al.   GUT

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

(2019) Clara Depommier et al.   NATURE MEDICINE

Interplay between the human gut microbiome and host metabolism

(2019) Alessia Visconti et al.   Nature Communications

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

(2019) Haiming Hu et al.   JOURNAL OF GASTROENTEROLOGY

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!

(2019) Golnaz Ranjbar et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

(2018) Teresa García-Lezana et al.   HEPATOLOGY

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

(2018) Pernille Wismann et al.   PHYSIOLOGY & BEHAVIOR

Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection

(2018) Christoph A. Thaiss et al.   SCIENCE

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice

(2018) Zi-Lun Lai et al.   Scientific Reports

The role of the microbiome in NAFLD and NASH

(2018) Aleksandra A Kolodziejczyk et al.   EMBO Molecular Medicine

Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease

(2017) Feng Shen et al.   Hepatobiliary & Pancreatic Diseases International

Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?

(2017) Daniel Jahn et al.   HEPATOLOGY

Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway

(2017) Bernardo Yusta et al.   Molecular Metabolism

Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases

(2017) Eugene Han et al.   Diabetes & Metabolism Journal

Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

(2017) Da Zhou et al.   Scientific Reports

The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites

(2016) Gerard E. Kaiko et al.   CELL

Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models

(2016) Mitsuaki Ishioka et al.   DIGESTIVE DISEASES AND SCIENCES

Pathogenesis of Nonalcoholic Steatohepatitis

(2016) Mariana Verdelho Machado et al.   GASTROENTEROLOGY

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus

(2016) Yuya Seko et al.   HEPATOLOGY RESEARCH

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism

(2016) Renee L. Greer et al.   Nature Communications

GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7

(2015) Jacqueline A. Koehler et al.   Cell Metabolism

Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella

(2015) Petia Kovatcheva-Datchary et al.   Cell Metabolism

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

(2015) Bernardo Yusta et al.   DIABETES

Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time

(2015) Cathrin Sellmann et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Another Agent for Obesity — Will This Time Be Different?

(2015) Elias S. Siraj et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease

(2015) Weiwei Jiang et al.   Scientific Reports

Changes in Gut Microbiota in Rats Fed a High Fat Diet Correlate with Obesity-Associated Metabolic Parameters

(2015) Virginie Lecomte et al.   PLoS One

Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration

(2014) Noura El-Jamal et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent

(2013) Laura Wrzosek et al.   BMC BIOLOGY

Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet

(2013) Sara Baldassano et al.   JOURNAL OF ENDOCRINOLOGY

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Deficiency in Interferon-γ Results in Reduced Body Weight and Better Glucose Tolerance in Mice

(2011) Nicole Wong et al.   ENDOCRINOLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Fibrogenic signalling in hepatic stellate cells

(2010) Derek A. Mann et al.   JOURNAL OF HEPATOLOGY

QIIME allows analysis of high-throughput community sequencing data

(2010) J Gregory Caporaso et al.   NATURE METHODS

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

(2009) Luca Miele et al.   HEPATOLOGY

Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2

(2008) Catherine P. A. Ivory et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY